Anti-gonadotrophin releasing hormone vaccine - ML Laboratories/Protherics
Alternative Names: GnRH immunotherapeutic; GnRH vaccine - ML Laboratories/Protherics; GnRHi; O14L; PM-OV-92; PrologLatest Information Update: 22 Jun 2004
Price :
$50 *
At a glance
- Originator Protherics
- Class Antiandrogens; Antiprogestogens; Vaccines
- Mechanism of Action Estrogen receptor antagonists; Gonadotropin releasing hormone inhibitors; Immunostimulants; Progesterone receptor antagonists; Testosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 22 Jun 2004 Discontinued - Phase-II for Prostate cancer in United Kingdom (unspecified route)
- 09 Jul 2001 Preliminary results of a phase II trial revealed that GnRHi did not elicit large reductions in testosterone levels and ML Laboratories may be about to discontinue the vaccine's development
- 01 Sep 2000 A phase II study of the new formulation of Prolog® in patients with late-stage prostate cancer is underway in the UK